Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label ataluren study in nonsense mutation Duchenne muscular dystrophy
CTR20211795Phase 3Completed
- Sponsor
- Laboratorios Farmacéuticos ROVI
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ataluren in Duchenne muscular dystrophy (DMD), sponsored by Laboratorios Farmacéuticos ROVI. Started Sep 2021; status: completed.
02
Drugs
ataluren
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on CTR20211795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211795.